irofulven has been researched along with thiazolyl blue in 2 studies
| Studies (irofulven) | Trials (irofulven) | Recent Studies (post-2010) (irofulven) | Studies (thiazolyl blue) | Trials (thiazolyl blue) | Recent Studies (post-2010) (thiazolyl blue) |
|---|---|---|---|---|---|
| 99 | 22 | 7 | 4,625 | 20 | 1,230 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cvitkovic, E; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ | 1 |
| Calvo, F; Cvitkovic, E; Koeppel, F; Laar, ES; Larsen, AK; Lokiec, F; Poindessous, V; Raymond, E; Serova, M; Waters, SJ | 1 |
2 other study(ies) available for irofulven and thiazolyl blue
| Article | Year |
|---|---|
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Coloring Agents; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Models, Chemical; Ovarian Neoplasms; Sesquiterpenes; Tetrazolium Salts; Thiazoles | 2003 |
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Genes, p53; HT29 Cells; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Sesquiterpenes; Tetrazolium Salts; Thiazoles | 2006 |